HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OGEN
Oragenics, Inc.
There isn't enough reported data to score OGEN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OGEN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
OGEN's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OGEN PE Valuation
OGEN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OGEN Forward outlook
There aren't enough analyst estimates for OGEN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
OGEN has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus OGEN down 111%.
OGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$24.05 | +$185.95 |
| Q2 2025 | -$33.49 | +$190.61 |
| Q1 2025 | -$45.69 | +$208.41 |
| Q4 2024 | -$63.09 | +$212.31 |
| Q3 2024 | -$210.00 | -$63.49 |
| Q2 2024 | -$224.10 | -$49.09 |
| Q1 2024 | -$254.10 | -$70.39 |
| Q4 2023 | -$275.40 | -$61.99 |
OGEN is still losing money, but far less than before: $24.05 per share over the past year, against $918.00 at its worst in mid-2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
OGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $7.5K | -91% |
| Q2 2023 | $13.2K | -57% |
| Q1 2023 | $17K | +13% |
OGEN's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -28053% | -23514 points |
| Q2 2023 | -23622% | -11763 points |
| Q1 2023 | -17063% | +13502 points |
| Q3 2022 | -4539% | N/A |
| Q2 2022 | -11859% | N/A |
| Q1 2022 | -30565% | N/A |
OGEN's operating margin was −28053% last quarter, down 16194 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
OGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | +$951.1K |
| Q2 2026 | -$2.2M | -$872.4K |
| Q1 2026 | -$2.2M | -$88.6K |
| Q4 2025 | -$2.8M | -$817.1K |
| Q3 2025 | -$3M | -$1M |
| Q2 2025 | -$1.3M | +$230.2K |
| Q1 2025 | -$2.1M | +$952.2K |
| Q4 2022 | -$2.4M | -$532.1K |
OGEN has burned cash in almost every quarter: −$9M over the past year, against −$8M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +83.4K shares |
| 1 year | +517% | +3.8M shares |
| 3 years | +6585% | +4.4M shares |
| 5 years | +7787% | +4.5M shares |
| Available history | +19107% | +4.5M shares |
OGEN has 5M diluted shares, up 517% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OGEN Net Leverage
OGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 5.7 | Oversold |
OGEN's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OGEN PE vs Healthcare Sector
OGEN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.42 | 17% below |
| 20 week MA | $0.48 | 27% below |
| 50 week MA | $0.63 | 44% below |
| 100 week MA | $2.60 | 87% below |
| 200 week MA | $41.7 | 99% below |
OGEN is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over OGEN on returns for 2026, with the stronger performance.
OGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $948.6 | $774.0 | -18% |
| 2021 | $774.0 | $867.8 | +12% |
| 2022 | $867.8 | $261.0 | -70% |
| 2023 | $261.0 | $168.9 | -35% |
| 2024 | $168.9 | $13.6 | -92% |
| 2025 | $13.6 | $0.86 | -94% |
| 2026 YTD | $0.86 | $0.35 | -59% |
OGEN has finished four years in a row lower, and it's down 59% so far in 2026.